KURA
Kura Oncology, Inc.
$9.05
+2.14%
$803.4M
No data for this timeframe.
Vol
Market Cap$803.4M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders50 funds
Inst. Value$274.6M
Inst. Activity12 buys / 10 sells
Insider Activity0B / 3S
Insider Net $-$151.6K
SEC Reports6
Press Releases6
Recent Activity
Jun 11, 2026
announcement
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
<p align="center"><em>– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML pat
Jun 4, 2026
Insider
Szela Mary T was granted 35,000 shares
Director
Jun 4, 2026
Insider
SCHAFER CAROL was granted 35,000 shares
Director
Jun 4, 2026
Insider
Malley Thomas was granted 35,000 shares
Director
Jun 3, 2026
Press
Kura Oncology presented Phase 1a data at ASCO 2026 showing darlifarnib + adagrasib achieved confirmed objective response
Impact 7/10
Jun 2, 2026
Press
Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitid
Impact 6/10
May 26, 2026
SEC
Kura Oncology filed a DEFA14A supplement addressing overboarding concerns regarding director nominee Mary T. Szela, who
DEFA14A — Impact 3/10
May 22, 2026
SEC
Three KURA C-suite insiders (COO, CLO, CCO) sold a total of $152K in open-market sales over a 7-day window, occurring 10
CLUSTER — Impact 2/10
Price Targets
$31.17
+244.4% upside
Strong Buy
Current $9.05
Low $15.00
Median $28.00
High $76.00
12 analysts
$15.00
$76.00
Analyst Ratings
6Strong Buy
13Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Lake Street | INITIATE | Buy |
| Mar 24, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 13, 2026 | UBS | MAINTAIN | Buy → Buy |
| Mar 6, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Jan 13, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.91 | $-1.02 — $-0.83 | -21% YoY | 8 |
| Next Q | $-0.93 | $-1.06 — $-0.84 | -9% YoY | 8 |
| Current FY | $-3.54 ▼ -0.6% | $-3.72 — $-3.33 | -11% YoY | 8 |
| Next FY | $-2.65 ▼ -3.9% | $-3.48 — $-2.12 | 25% YoY | 9 |
Latest Reports
BULLISH
Press
7/10
Kura Oncology presented Phase 1a data at ASCO 2026 showing darlifarnib + adagrasib achieved confirmed objective response
Jun 3, 2026
NEUTRAL
DEFA14A
3/10
Kura Oncology filed a DEFA14A supplement addressing overboarding concerns regarding director nominee Mary T. Szela, who
May 26, 2026
NEUTRAL
CLUSTER
2/10
Three KURA C-suite insiders (COO, CLO, CCO) sold a total of $152K in open-market sales over a 7-day window, occurring 10
May 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $78.4M | — |
| STATE STREET CORP | $36.7M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $30.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $12.9M | DOUBLED |
| GOLDMAN SACHS GROUP INC | $11.7M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Szela Mary | A | $0.00 |
| Jun 4, 2026 | SCHAFER CAROL | A | $0.00 |
| Jun 4, 2026 | Malley Thomas | A | $0.00 |
| Jun 4, 2026 | Parks Diane | A | $0.00 |
| Jun 4, 2026 | VASCONCELLES MICHAEL | A | $0.00 |
50 institutional holders with $274.6M total value (33,758,493 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 12 institutions added/increased vs 10 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9,637,531 | $78.4M | 28.5% | — |
| 2 | STATE STREET CORP | 4,511,891 | $36.7M | 13.4% | ADD +47.5% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3,785,685 | $30.8M | 11.2% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 1,582,568 | $12.9M | 4.7% | DOUBLED +111.6% |
| 5 | GOLDMAN SACHS GROUP INC | 1,433,471 | $11.7M | 4.2% | — |
| 6 | DIMENSIONAL FUND ADVISORS LP | 1,425,945 | $11.6M | 4.2% | ADD +32.3% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,230,802 | $10.0M | 3.6% | — |
| 8 | BANK OF AMERICA CORP /DE/ | 1,230,131 | $10.0M | 3.6% | ADD +46.1% |
| 9 | MORGAN STANLEY | 1,163,977 | $9.5M | 3.4% | — |
| 10 | Connor, Clark & Lunn Investment Management Ltd. | 800,597 | $6.5M | 2.4% | ADD +29.4% |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 690,817 | $5.6M | 2.0% | — |
| 12 | VANGUARD FIDUCIARY TRUST CO | 554,983 | $4.5M | 1.6% | — |
| 13 | Trexquant Investment LP | 528,704 | $4.3M | 1.6% | DOUBLED +132.5% |
| 14 | CITADEL ADVISORS LLC | 368,825 | $3.0M | 1.1% | DOUBLED +122.1% |
| 15 | TWO SIGMA INVESTMENTS, LP | 357,955 | $2.9M | 1.1% | DOUBLED +130.5% |
| 16 | Assenagon Asset Management S.A. | 339,712 | $2.8M | 1.0% | TRIM -70.3% |
| 17 | GREAT LAKES ADVISORS, LLC | 339,599 | $2.8M | 1.0% | — |
| 18 | SEI INVESTMENTS CO | 319,266 | $2.6M | 0.9% | ADD +74.0% |
| 19 | FMR LLC | 317,652 | $2.6M | 0.9% | DOUBLED +252.9% |
| 20 | ExodusPoint Capital Management, LP | 229,728 | $1.9M | 0.7% | DOUBLED +835.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | ADD | 1,077,818 | 1,425,945 | +32.3% | $11.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 842,128 | 1,230,131 | +46.1% | $10.0M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 618,571 | 800,597 | +29.4% | $6.5M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 227,382 | 528,704 | +132.5% | $4.3M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 1,145,016 | 339,712 | -70.3% | $2.8M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 183,448 | 319,266 | +74.0% | $2.6M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 24,553 | 229,728 | +835.6% | $1.9M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 346,676 | 226,160 | -34.8% | $1.8M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 187,391 | 134,152 | -28.4% | $1.1M | 2026-Q1 |
| Mariner, LLC | TRIM | 125,920 | 92,811 | -26.3% | $754.4K | 2026-Q1 |
| HSBC HOLDINGS PLC | ADD | 52,003 | 89,032 | +71.2% | $736.3K | 2026-Q1 |
| Brevan Howard Capital Management LP | ADD | 44,843 | 84,575 | +88.6% | $687.6K | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 160,031 | 83,533 | -47.8% | $679.1K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 92,200 | 41,280 | -55.2% | $335.6K | 2026-Q1 |
| NOMURA HOLDINGS INC | TRIM | 33,574 | 14,985 | -55.4% | $121.8K | 2026-Q1 |
| FRANKLIN RESOURCES INC | NEAR_EXIT | 281,115 | 14,353 | -94.9% | $116.7K | 2026-Q1 |
| Merit Financial Group, LLC | TRIM | 22,499 | 13,569 | -39.7% | $110.3K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 596 | 1,500 | +151.7% | $12.2K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 763 | 1,326 | +73.8% | $10.8K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | NEAR_EXIT | 23,296 | 823 | -96.5% | $6.7K | 2026-Q1 |
| HRT FINANCIAL LP | DOUBLED | 98,029 | 449,024 | +358.1% | $3.6K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 45,727 | 58,094 | +27.0% | $473.00 | 2026-Q1 |
| STATE STREET CORP | ADD | 3,343,131 | 4,931,090 | +47.5% | $51.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 865,310 | 1,830,566 | +111.6% | $19.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 572,175 | 842,128 | +47.2% | $8.7M | 2025-Q4 |
11 unique insiders with 12 transactions. Net insider value: -$151.6K ($0.00 bought, $151.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Szela Mary T | Director | AWARD | 35,000 | — | — |
| Jun 4, 2026 | SCHAFER CAROL | Director | AWARD | 35,000 | — | — |
| Jun 4, 2026 | Malley Thomas | Director | AWARD | 35,000 | — | — |
| Jun 4, 2026 | Parks Diane L. | Director | AWARD | 35,000 | — | — |
| Jun 4, 2026 | VASCONCELLES MICHAEL | Director | AWARD | 35,000 | — | — |
| Jun 4, 2026 | Hasnain Faheem | Director | AWARD | 35,000 | — | — |
| Jun 4, 2026 | Collins Helen Louise | Director | AWARD | 35,000 | — | — |
| May 21, 2026 | Powl Brian T. | Chief Commercial Officer | SELL | 10,000 | $11.00 | $110.0K |
| May 19, 2026 | FORD KATHLEEN | Chief Operating Officer | SELL | 2,257 | $9.08 | $20.5K |
| May 18, 2026 | Bair Teresa Brophy | Chief Legal Officer | SELL | 2,256 | $9.38 | $21.2K |
| Mar 23, 2026 | WILSON TROY EDWARD | President and CEO | EXERCISE | 6,103 | $6.15 | $37.5K |
| Mar 18, 2026 | Malley Thomas | Director | EXERCISE | 10,000 | $3.12 | $31.2K |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 4.0/10.
NEUTRAL
DEFA14A
3/10
Kura Oncology filed a DEFA14A supplement addressing overboarding concerns regarding director nominee
May 26, 2026
NEUTRAL
CLUSTER
2/10
Three KURA C-suite insiders (COO, CLO, CCO) sold a total of $152K in open-market sales over a 7-day
May 22, 2026
NEUTRAL
8-K
5/10
Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product revenue (first full commercial
May 12, 2026
NEUTRAL
DEFA14A
2/10
Kura Oncology is holding its annual shareholder meeting to vote on director elections, auditor appoi
Apr 10, 2026
MIXED
8-K
6/10
Kura Oncology reported its first commercial revenue of $2.1 million from KOMZIFTI, its newly approve
Mar 5, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
BULLISH
7/10
Kura Oncology presented Phase 1a data at ASCO 2026 showing darlifarnib + adagrasib achieved confirme
Jun 3, 2026
BULLISH
6/10
Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + v
Jun 2, 2026
BULLISH
7/10
Kura Oncology reported positive first-in-human Phase 1a data for darlifarnib plus adagrasib in KRAS
May 26, 2026
BULLISH
7/10
Kura Oncology announced that updated Phase 1 KOMET-007 data for ziftomenib in frontline AML will be
May 12, 2026
BULLISH
8/10
Kura Oncology announced preliminary clinical data from a subset of patients with clear cell renal ce
Apr 17, 2026
BULLISH
8/10
Kura Oncology reported Q4 and full-year 2025 financial results, highlighted by $2.1 million in net p
Mar 5, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 22 analysts: 6 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$31.17 mean target
+244.4% upside
Strong Buy (1.27)
$15.00 Low
$76.00 High
| Metric | Value |
|---|---|
| Current Price | $9.05 |
| Target Low | $15.00 |
| Target Mean | $31.17 |
| Target Median | $28.00 |
| Target High | $76.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.27) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.91 | $-1.02 | $-0.83 | -20.8% | +0.0% | 7↑ 1↓ | $0.0B | 28.6% | 8 |
| Next Q 2026-09-30 |
$-0.93 | $-1.06 | $-0.84 | -9.0% | +0.0% | 7↑ 1↓ | $0.0B | 9.7% | 8 |
| Current FY 2026-12-31 |
$-3.54 | $-3.72 | $-3.33 | -11.4% | -0.6% | 5↑ 3↓ | $0.1B | 40.6% | 8 |
| Next FY 2027-12-31 |
$-2.65 | $-3.48 | $-2.12 | 25.1% | -3.9% | 5↑ 3↓ | $0.2B | 126.1% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.906 | |
| 7d ago | $-0.906 | |
| 30d ago | $-0.906 | |
| 60d ago | $-0.946 | +0.040 |
| 90d ago | $-0.979 | +0.072 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Lake Street | INITIATE | — | Buy |
| Mar 24, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 13, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 13, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Jan 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 13 | 3 | 0 | 0 | 86% | |
| May 1, 2026 | 6 | 13 | 3 | 0 | 0 | 86% | |
| Apr 1, 2026 | 6 | 12 | 3 | 0 | 0 | 86% | |
| Mar 1, 2026 | 6 | 12 | 3 | 0 | 0 | 86% | |
| Feb 1, 2026 | 6 | 12 | 3 | 0 | 0 | 86% | |
| Jan 1, 2026 | 6 | 12 | 3 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
announcement
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
<p align="center"><em>– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –</em></p>
Jun 5, 2026
Clinical Trial
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Phase Phase 2 — COMPLETED
Jun 5, 2026
other
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company comm
Jun 5, 2026
short_volume
Short Volume: KURA — 62.1% short (0.5M / 0.7M)
Short: 458,535 | Exempt: 16 | TRF Vol: 737,888 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: KURA — 59.3% short (0.4M / 0.7M)
Short: 419,123 | Exempt: 0 | TRF Vol: 707,180 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
fda
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
<p align="center"><em>– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic ca
Jun 3, 2026
short_volume
Short Volume: KURA — 66.0% short (0.4M / 0.6M)
Short: 403,483 | Exempt: 651 | TRF Vol: 611,159 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
fda
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
<p align="center"><em>– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg o
Jun 2, 2026
short_volume
Short Volume: KURA — 66.6% short (0.6M / 1.0M)
Short: 639,061 | Exempt: 11,535 | TRF Vol: 959,034 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: KURA — 62.0% short (0.5M / 0.8M)
Short: 496,582 | Exempt: 6,062 | TRF Vol: 800,489 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
<p align="center"><em>– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients
May 19, 2026
other
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
<p align="justify">SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen
May 13, 2026
short_volume
Short Volume: KURA — 61.7% short (0.6M / 0.9M)
Short: 556,399 | Exempt: 2,371 | TRF Vol: 901,769 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
Kura Oncology Reports First Quarter 2026 Financial Results
<p align="center"><em>– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization –</em></p>
May 12, 2026
fda
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
<p align="center"><em>– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –</em></p>
May 12, 2026
earnings_calendar
KURA Q1 2026 Earnings Scheduled — 2026-05-12